Internal Versus External Electrical Cardioversion of Atrial Arrhythmia in Patients With Implantable Cardioverter-Defibrillator : A Randomized Clinical Trial

Medientyp: E-Artikel
Titel: Internal Versus External Electrical Cardioversion of Atrial Arrhythmia in Patients With Implantable Cardioverter-Defibrillator : A Randomized Clinical Trial : A Randomized Clinical Trial
Beteiligte: Lüker, Jakob; Kuhr, Kathrin; Sultan, Arian; Nölker, Georg; Omran, Hazem; Willems, Stephan; Andrié, René; Schrickel, Jan W.; Winter, Stefan; Vollmann, Dirk; Tilz, Roland R.; Jobs, Alexander; Heeger, Christian-H.; Metzner, Andreas; Meyer, Sven; Mischke, Karl; Napp, Andreas; Fahrig, Andreas; Steinhauser, Susanne; Brachmann, Johannes; Baldus, Stephan; Mahajan, Rajiv; Sanders, Prashanthan; Steven, Daniel
Erschienen: Ovid Technologies (Wolters Kluwer Health), 2019
Erschienen in: Circulation
Sprache: Englisch
DOI: 10.1161/circulationaha.119.041320
ISSN: 0009-7322; 1524-4539
Entstehung:
Anmerkungen:
Beschreibung: <jats:sec> <jats:title>Background:</jats:title> <jats:p>Atrial arrhythmias are common in patients with implantable cardioverter-defibrillator (ICD). External shocks and internal cardioversion through commanded ICD shock for electrical cardioversion are used for rhythm-control. However, there is a paucity of data on efficacy of external versus internal cardioversion and on the risk of lead and device malfunction. We hypothesized that external cardioversion is noninferior to internal cardioversion for safety, and superior for successful restoration of sinus rhythm.</jats:p> </jats:sec> <jats:sec> <jats:title>Methods:</jats:title> <jats:p>Consecutive patients with ICD undergoing elective cardioversion for atrial arrhythmias at 13 centers were randomized in 1:1 fashion to either internal or external cardioversion. The primary safety end point was a composite of surrogate events of lead or device malfunction. Conversion of atrial arrhythmia to sinus rhythm was the primary efficacy end point. Myocardial damage was studied by measuring troponin release in both groups.</jats:p> </jats:sec> <jats:sec> <jats:title>Results:</jats:title> <jats:p> N=230 patients were randomized. Shock efficacy was 93% in the external cardioversion group and 65% in the internal cardioversion group ( <jats:italic>P</jats:italic> <0.001). Clinically relevant adverse events caused by external or internal cardioversion were not observed. Three cases of pre-existing silent lead malfunction were unmasked by internal shock, resulting in lead failure. Troponin release did not differ between groups. </jats:p> </jats:sec> <jats:sec> <jats:title>Conclusions:</jats:title> <jats:p>This is the first randomized trial on external vs internal cardioversion in patients with ICDs. External cardioversion was superior for the restoration of sinus rhythm. The unmasking of silent lead malfunction in the internal cardioversion group suggests that an internal shock attempt may be reasonable in selected ICD patients presenting for electrical cardioversion.</jats:p> </jats:sec> <jats:sec> <jats:title>Clinical Trial Registration:</jats:title> <jats:p> URL: <jats:ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.clinicaltrials.gov">https://www.clinicaltrials.gov</jats:ext-link> . Unique identifier: NCT03247738. </jats:p> </jats:sec>
Zugangsstatus: Freier Zugang

Nur in Feld suchen:

Zuletzt gesuchte Begriffe: